AI Article Synopsis
- - Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate specifically designed to target and treat HER2-positive cancers, delivering a drug directly to cancer cells to promote cell death and slow tumor growth.
- - Clinical trials have demonstrated T-DXd's effectiveness in advanced or metastatic cancers like breast, gastric, lung, and colorectal, leading to its recent FDA approval for HER2-positive solid tumors.
- - New findings suggest T-DXd is not only effective against brain metastasis but also shows potential benefits for patients with HER2-low and HER2-ultra-low metastatic breast cancer, expanding the range of patients who can be treated.
Article Abstract
Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate (ADC) targeting HER2-positive malignancies across various tumor types. Through its unique composition, T-DXd achieves selective payload delivery, inducing cell death and halting tumor progression. Clinical trials initially investigated T-DXd's efficacy in HER2-positive advanced or metastatic breast, gastric, lung, and colorectal cancers; however, recent results from the DESTINY-PanTumor02 trial further underscore T-DXd's versatility, prompting T-DXd's US FDA approval for HER2-positive (immunohistochemistry [IHC] 3+) solid tumors. Moreover, in addition to T-DXd's efficacy against brain metastasis, T-DXd is showing promising results in HER2-low and HER2-ultra-low metastatic breast cancer, indicating a broader population of patients who may benefit.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11523-024-01079-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!